Morgan Stanley Io Biotech, Inc. Call Options Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IOBT
# of Institutions
20Shares Held
24.8MCall Options Held
988KPut Options Held
0-
Vivo Capital, LLC Palo Alto, CA6.17MShares$8.21 Million1.07% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.64MShares$4.84 Million2.19% of portfolio
-
Novo Holdings Hellerup, G73.35MShares$4.46 Million0.25% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.34MShares$3.11 Million0.14% of portfolio
-
Marshall Wace, LLP London, X02.11MShares$2.8 Million0.0% of portfolio
About IO Biotech, Inc.
- Ticker IOBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,815,300
- Market Cap $38.3M
- Description
- IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in ph...